H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $46 from $32 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s shift towards a more royalty-focused strategy for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks: Strengthened Liquidity and Preserved Zanidatamab Royalty Upside Support Overweight Rating
- Zymeworks price target raised to $47 from $40 at Stifel
- Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty
- Morning Movers: Travel stocks fall following U.S.-Israeli strikes on Iran
- Zymeworks Monetizes Ziihera Royalties to Boost Liquidity